NEW YORK, Sept. 23, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) between February 25, 2016 and August 1, 2016. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/keryx-biopharmaceuticals-inc
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company was experiencing production-related difficulties in converting API to finished drug product; (2) that the issue was resulting in decreased production yields of finished drug product; (3) that, as a result, the Company would, and did exhaust its reserve of finished drug product; and (4) that, as a result of the foregoing, Defendants’ statements about Keryx’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Keryx Biopharmaceuticals, Inc. you have until October 3, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Apple Turns 50: From Garage Startup to AI Crossroads
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 



